ImmunOs Therapeutics will use ProBioGen’s proprietary Pathway Modulator Technology for the development of its pipeline of novel complex recombinant proteins.

The Pathway Modulator is based on the stable expression of an optimized key-regulator enzyme acting on multiple pathways involved in cellular protein expression and protein secretion. The combination of ProBioGen’s DirectedLuck transposase technology for high transgene expression and the Pathway Modulator technology boosts the specific productivity with no compromises on the cell’s growth properties. The Pathway Modulator can be applied to already existing cell lines or from scratch on during cell line development.

Together with the DirectedLuck Transposase, ImmunOs will use the Pathway Modulator to increase the protein yield of selected candidates of their pipeline of novel complex recombinant proteins.

Dr. Volker Sandig, Chief Scientific Officer of ProBioGen: “This is yet another milestone for ProBioGen’s technology platform and we are glad to support the advancement of ImmunOs’ pipeline agents into the next phase.”